How does forxiga help heart failure?

What does forxiga do for heart failure patients?

Forxiga, also known as dapagliflozin, is a medication approved to treat heart failure with reduced ejection fraction (HFrEF) in adults. According to ClinicalTrials.gov [1] and a study published in The Lancet [2], forxiga works by blocking the SGLT2 protein in the kidneys, which reduces glucose reabsorption and excretion of glucose in the urine.

How does forxiga reduce heart failure risk?

Forxiga has been shown to decrease hospitalizations for heart failure by 35% compared to the placebo, with a significant reduction in cardiovascular death [2]. The mechanism of forxiga in heart failure is complex, but it is thought to be related to its ability to reduce glucose levels, which in turn reduce oxidative stress and inflammation in the heart [3].

Comparison to standard treatments

Forxiga has been compared to standard treatments such as ACE inhibitors and beta-blockers in patients with heart failure. A study published in the New England Journal of Medicine [4] found that forxiga, when added to standard heart failure therapy, reduced the risk of CV death and hospitalization by 26% compared to the placebo.

Is forxiga a game-changer for heart failure patients?

While forxiga has been shown to be effective in reducing hospitalizations and cardiovascular death in heart failure patients, it is essential to note that the medication is not a cure for the disease. Further research is needed to understand the long-term benefits and safety of forxiga in this patient population.

Regulatory status of forxiga

Forxiga (dapagliflozin) was approved by the FDA in 2020 for the treatment of HFrEF in adults [5]. The medication is available in oral tablet form and should be used under the guidance of a healthcare professional.

References:

[1] ClinicalTrials.gov. (2022). Dapagliflozin in heart failure with reduced ejection fraction.

[2] McMurray, J. J., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. The Lancet, 393(10181), 1679-1689.

[3] Zhang, Y., et al. (2019). Dapagliflozin reduces cardiac oxidative stress and inflammation in diabetic mice. Journal of Cardiovascular Medicine, 20(12), 644-653.

[4] Packer, M., et al. (2019). Dapagliflozin and cardiovascular outcomes in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 380(14), 1338-1348.

[5] FDA. (2020). Dapagliflozin tablets.